Hepatitis B virus articles from across Nature Portfolio

Hepatitis B virus is an ancient human pathogen that dates back more than 10,000 years. Here, the authors investigate the evolutionary history of the virus in Eastern Eurasia by sequencing 34 genomes dating from approximately 400–5,000 years ago and comparing them with other contemporary sequences.

The nuclear dot protein 52 (NDP52) is an autophagy receptor known to trigger autophagy following bacterial infection. Here, Cui et al. show that NDP52 also triggers an anti-viral response following hepatitis B virus (HBV) infection. NDP52 forms a tripartite complex with Rab9 and envelope proteins of HBV and targets the virus to Rab9-dependent lysosomal degradation pathway.

There is increasing evidence that treatment of hepatitis B with interferon alpha can be beneficial. Here, Wang et al, present a type 1 interferon receptor humanized mouse model and characterize it as a platform in which to study interferon function in vivo.

The mechanism by which the chromatinized HBV genome is transcribed remains poorly understood. In this study, Liu et al. demonstrate how HBx exploits Spindlin1, a histone methylation reader, to overcome heterochromatin barriers and enhance HBV transcription from the cccDNA minichromosome.

Hepatitis B virus is an almost uniquely human-tropic pathogen for which model systems are scarce. Here, the authors determine key residues within the HBV receptor that form a barrier in the HBV life cycle in primates and identify marmosets as a model candidate for infection with simian-tropic HBV.

Progress towards hepatitis B virus (HBV) elimination targets remains slow, despite efforts to support enhanced prevention, diagnosis and treatment. On the basis of insights from interventions against HIV, we argue for the wider use of antiviral therapy for HBV, highlighting the potential public health benefits in preventing liver disease and reducing transmission.

More than 250 million people worldwide are chronically infected with the hepatitis B virus (HBV). In this Comment, members of the International Coalition to Eliminate HBV appraise the current policy environment and the need for appropriate cure research and preparedness to complement the WHO global elimination strategy, the HBV vaccine and the well-tolerated but poorly accessed therapy.